New combo therapy shows promise for Hard-to-Treat head and neck cancer
NCT ID NCT01468896
First seen Mar 28, 2026 · Last updated Jun 18, 2026 · Updated 9 times
Summary
This study tests a combination of two drugs—cetuximab and interleukin-12—in people with head and neck cancer that has returned, spread, or cannot be removed by surgery. The goal is to find the safest dose of interleukin-12 and see if the pair can shrink tumors. About 23 adults with advanced squamous cell carcinoma of the head and neck are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.